WO2015115072A1 - カプセル製剤 - Google Patents
カプセル製剤 Download PDFInfo
- Publication number
- WO2015115072A1 WO2015115072A1 PCT/JP2015/000291 JP2015000291W WO2015115072A1 WO 2015115072 A1 WO2015115072 A1 WO 2015115072A1 JP 2015000291 W JP2015000291 W JP 2015000291W WO 2015115072 A1 WO2015115072 A1 WO 2015115072A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- capsule
- aqueous solution
- weight
- agar
- parts
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
Definitions
- the present invention relates to a capsule preparation, and more particularly to a capsule preparation in which a capsule content in which an aqueous solution is encapsulated in an oily substance containing porous fine particle powder is encapsulated with a hydrophilic film.
- water is used as the solvent for the hydrophilic substance.
- gelatin or a mixture of agar and water-soluble polymer is used as the coating material, a capsule preparation containing water-containing material can be manufactured. Softening of the capsule film occurs due to the compatibility between the coating liquid and water and the transfer of water after encapsulation. Therefore, the present situation is that a hydrophilic substance cannot be encapsulated in a stable state.
- the film is hydrophilic, so if the material containing water, for example, food extracts such as garlic extract, coffee extract, aloe vera extract is encapsulated, the film dissolves in water. There's a problem. Therefore, the encapsulated material must be powdered or suspended in hardened oil and encapsulated in a capsule.
- a film is formed from a mixed solution obtained by dissolving agar in water and adding a water-soluble polymer such as carrageenan. Since such a film is also hydrophilic, there is a problem that when a material containing water is encapsulated, the film is dissolved by water, which is used when encapsulating contents dissolved in fats and oils (see Patent Document 3).
- a method for producing a capsule using an alginate as a coating material for example, a liquid formed by dispersing or dissolving a desired material in an aqueous solution of sodium alginate and dropping it into an aqueous solution of a polyvalent metal salt.
- a method is known in which a water-insoluble film is formed on the outside of a droplet, and further solidified to the inside of the droplet to obtain a strong capsule (see Patent Document 4).
- Such a method requires complicated steps such as washing and drying in the production of capsule preparations.
- the present invention has been made in view of the conventional situation as described above, and is a capsule preparation that can stably retain a hydrophilic substance for a long period of time and can further contain a mixture contraindicated component in the same capsule. It is an issue to provide.
- the present inventors prepared an in-capsule solution by adding an aqueous solution in which a hydrophilic substance was dissolved to a mixed liquid obtained by adding porous fine particle powder to edible oil.
- a capsule preparation was prepared by encapsulating the capsule contents with a gelatin film, the gelatin film was not softened, and the hydrophilic substance was kept stable even if the incompatible ingredients were contained in the same capsule.
- the present invention has been completed.
- the present invention relates to [1] a capsule preparation in which an aqueous solution is encapsulated in an oily substance containing porous fine particle powder, and [2] 100 parts by weight of the oily substance.
- the capsule preparation described in [1] or [2] above wherein the capsule preparation described in [1] above or the capsule preparation described in [3] is a soft capsule preparation.
- a capsule preparation that can stably hold a hydrophilic substance in an aqueous solution for a long period of time and further can contain incompatible ingredients in the same capsule.
- FIG. 2 is a photograph of agar particles containing soft capsules obtained in Example 1.
- the capsule preparation of the present invention is not particularly limited as long as it is a capsule preparation in which an oily substance containing porous fine particle powder is encapsulated with an aqueous solution and encapsulated with a hydrophilic film, but is a soft capsule preparation. Can be preferably mentioned.
- examples of the porous fine particle powder include known fine particle powders such as amorphous synthetic silica such as gas phase method silica and wet method silica, alumina, hydrated alumina, calcium carbonate, magnesium carbonate, and titanium dioxide.
- amorphous synthetic silica such as gas phase method silica or wet method silica, alumina or alumina hydrate, more preferably gas phase method silica or wet method silica.
- Amorphous synthetic silica, more preferably gas phase method silica can be mentioned.
- Amorphous synthetic silica is classified into vapor phase silica, wet method silica and other silicas according to the production method, and wet method silica is further classified into precipitation method silica, gel method silica and sol method silica according to the production method. .
- Vapor phase silica is also called a dry method as opposed to a wet method, and is generally made by a flame hydrolysis method.
- a method of making silicon tetrachloride by burning with hydrogen and oxygen is generally known, but silanes such as methyltrichlorosilane and trichlorosilane can be used alone or silicon tetrachloride instead of silicon tetrachloride.
- Precipitated silica is produced by reacting sodium silicate and sulfuric acid under alkaline conditions, and the silica particles that have grown are agglomerated and settled, followed by filtration, washing with water, drying, pulverization and classification.
- NIPSEAL registered trademark
- Tosoh Silica Co., Ltd. is commercially available.
- Gel silica is produced by reacting sodium silicate and sulfuric acid under acidic conditions. During the ripening, the fine particles dissolve and reprecipitate so as to bind other primary particles, so that the distinct primary particles disappear and form relatively hard aggregated particles having an internal void structure.
- Nipgel registered trademark
- siloid manufactured by Tosoh Silica
- silojet produced by Grace Japan
- the sol method silica is also referred to as colloidal silica, and is obtained by heating and aging a silica sol obtained through metathesis of sodium silicate acid or the like through an ion exchange resin layer.
- sol method silica Snowtex (registered trademark) (manufactured by Nissan Chemical Industries, Ltd.) is commercially available.
- the specific surface area of the porous fine particle powder is 100 m 2 / g or more, preferably 100 to 500 m 2 / g.
- two or more kinds of porous fine particle powders can be used in combination.
- combined use of pulverized gas phase method silica and wet method silica, combination use of finely pulverized wet method silica and alumina or alumina hydrate, and combination use of gas phase method silica and alumina or alumina hydrate. can be mentioned.
- oily substance in the present invention safflower oil, linseed oil, sesame oil, olive oil, soybean oil, mustard oil, rapeseed oil, corn oil, castor oil, evening primrose oil, palm kernel oil, jojoba oil, cottonseed oil, coconut oil, Peanut oil, cacao oil, lard, EPA, DHA, shark liver oil, cod liver oil, hydrogenated oil, partially hardened oil and other animal and vegetable oils, medium chain fatty acid triglycerides (MCT), glycerin fatty acid esters, fatty acid acyl esters, paraffins MCT can be preferably mentioned.
- MCT medium chain fatty acid triglycerides
- oily substances Two or more of the above oily substances may be combined, but when a mixture of a high melting point oily substance and a low melting point oily substance is used, the ratio of the high melting point oily substance to the low melting point oily substance is 1:10. It is preferable that the ratio is ⁇ 10: 1. In this case, it is preferable to use oily substances having similar structures.
- the oily substance is preferably liquid at room temperature, and the melting point of the oily substance is preferably ⁇ 40 to 40 ° C., particularly preferably ⁇ 30 to 20 ° C.
- the content of the porous fine particle powder is 0.1 to 20 parts by weight, preferably 5 to 15 parts by weight, and more preferably 6 to 10 parts by weight with respect to 100 parts by weight of the oily substance.
- an oily substance containing porous fine particle powder As a method for preparing an oily substance containing porous fine particle powder, it is only necessary to add and disperse the porous fine particle powder to the oily substance.
- a dispersion method in addition to stirring by hand, propeller stirring, turbine type Conventionally known methods such as stirring and homomixer type stirring can be used.
- the oily substance may further contain components other than the porous fine particle powder.
- the aqueous solution is not particularly limited as long as water or a liquid substance in which a hydrophilic substance is dissolved in water, and a plurality of hydrophilic substances may be dissolved in water.
- the hydrophilic substance in the present invention has a functional group that easily forms a bond with a water molecule such as a hydroxyl group, a carboxyl group, an amino group, a ketone group, and a sulfo group in a part of the molecular structure and is soluble in water.
- the aqueous solution may contain components other than hydrophilic substances and water, such as water extracts such as food extracts such as blueberry extract, lemon juice, garlic extract and shijimi extract, and pharmaceutical extracts such as carrot extract and toki extract. Also included is a liquid material having a content of 15 to 40% and low fluidity.
- water-soluble polymers such as agar, gelatin, sodium carrageenan alginate, pullulan, glucomannan, gum arabic, fur celerane, yukema algae, gellan gum, hydroxypropyl methylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, starches, etc.
- Soft granules produced by dissolution are also included in the aqueous solution for convenience.
- the content of the aqueous solution may be 0.01 to 80 parts by weight, preferably 0.1 to 40 parts by weight, and more preferably 0.2 to 20 parts by weight with respect to 100 parts by weight of the oily substance.
- the content of water in the aqueous solution can be adjusted as appropriate according to the amount of the hydrophilic substance to be dissolved, but is preferably an amount capable of dissolving the hydrophilic substance to be dissolved.
- the aqueous solution is encapsulated in the oily substance is not particularly limited as long as the aqueous solution is covered with the oily substance and the aqueous solution exists inside the oily substance, and the number of aqueous solutions encapsulated in the oily substance. May be one or more.
- an aqueous solution is added to an oily substance containing porous fine particle powder and stirred. be able to.
- the added aqueous solution may be separated into a plurality of aqueous solutions by stirring and encapsulated in an oily substance.
- Capsule contents containing a hydrophilic substance dissolved in an aqueous solution and a mixed contraindication component can also be produced.
- a method for producing the contents for capsules there are a method of adding an incompatible component of powder together with an aqueous solution to an oily substance containing porous fine particle powder and stirring, and a mixed repellent component of porous fine particle powder and powder. Examples of the method include preparing an oily substance to be contained, adding an aqueous solution to the oily substance, and stirring the oily substance.
- the method for preparing the oily substance containing the porous fine particle powder and the mixed repellent component of the powder is the same as the method for preparing the oily substance containing the porous fine particle powder.
- incompatible ingredients are hydrophobic
- the hydrophilic film is not particularly limited as long as it is a film produced using a hydrophilic substance as a film material. Even if the film is hydrophilic, the aqueous solution in the capsule content is oily. Since it is contained in the substance, the water contained in the aqueous solution does not come into contact with the film, and the film does not soften.
- Coating materials include gelatin, carrageenan, agar, sodium alginate, pullulan, glucomannan, gum arabic, fur celerane, yukema algae, gellan gum, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, starches, etc.
- Molecules can be mentioned, and gelatin can be preferably mentioned.
- the film material When producing a hydrophilic film, the film material is gelled with plasticizers such as glycerin, pH adjusters such as sodium phosphate, chelating agents such as trisodium citrate and sodium metaphosphate, calcium lactate and potassium chloride. Accelerators, surfactants such as polyglycerin fatty acid esters and lecithin, sweeteners, fragrances, preservatives, colorants and the like may be added.
- the capsule preparation of the present invention is manufactured by encapsulating the capsule contents with a hydrophilic film using a known capsule preparation manufacturing method such as a flat plate method, a rotary die method, or a seamless method.
- the major axis of the capsule preparation is not particularly limited, and examples thereof include 1 to 50 mm, preferably 5 to 20 mm.
- the agar solution for agar fine particles was dropped using a seamless soft capsule production apparatus to produce soft agar fine particles having a diameter of about 1 mm.
- the capsule contents were encapsulated with the capsule film solution by a rotary die type soft capsule production apparatus, and then dried at 30 ° C. for 20 hours to produce agar-fine soft capsules.
- the obtained agar fine particle-containing soft capsules contained about 10 agar fine particles.
- the agar fine particles were soft and retained moisture even after the drying process in capsule production.
- the obtained agar fine particle-containing soft capsules were stored at 40 ° C. for 6 months.
- a photograph of the soft capsule containing agar fine particles after storage is shown in FIG.
- the points indicated by arrows in the capsule contents are the agar granules.
- Observation of the agar granules encapsulated in the agar granules-containing soft capsules after storage revealed that they were as soft as the agar granules encapsulated in the agar granules-containing soft capsules immediately after the capsules were produced, and retained moisture to the same extent. Furthermore, the film did not soften.
- Example 1 Manufacture of capsule containing agar fine particles by conventional technology
- agar-containing soft capsules were produced under the same conditions as above except that the same amount of beeswax was used instead of Aerosil RX200.
- the obtained agar fine particle-containing soft capsules contained about 10 agar fine particles.
- the agar granules were soft immediately after production and retained moisture.
- the obtained agar fine particle-containing soft capsules were stored at 40 ° C. for 6 months.
- the soft capsules after storage were softened and the capsules were fused.
- water was evaporated from the agar granules, and only the residue was observed.
- the capsule preparation of the present invention when used, it is possible to hold an aqueous solution that could not be encapsulated or held in a conventional capsule preparation for a long period of time, and even if a hydrophilic film is used, the capsule contents It was revealed that the film was not softened by the aqueous solution of the product.
- the obtained dispersion was put in a centrifuge tube and centrifuged at 2000 rpm for 5 minutes in a centrifuge. Even after centrifugation, the colored water and MCT were not separated, and the dispersion was uniform.
- the obtained dispersion was put in a centrifuge tube and centrifuged at 2000 rpm for 5 minutes in a centrifuge. Even after centrifugation, the colored water and MCT were not separated, and the dispersion was uniform.
- the aqueous solution can be maintained in the MCT-Aerosil mixture, and when used as a capsule content, It is possible to prevent evaporation and softening of the film.
- Soft capsules were produced by a rotary die type soft capsule production apparatus using the capsule contents described in Example 1 and the capsule contents containing the cyanocobalamin aqueous solution.
- the obtained cyanocobalamin-containing soft capsule preparation was stored at 40 ° C. for 1 month.
- the aqueous solution maintained the same amount as immediately after the capsule was produced, and the film did not soften.
- the amount of cyanocobalamin immediately after the production of the soft capsule and after storage for 1 month was measured using a high performance liquid chromatography method. The results are shown in Table 1.
- the amount of cyanocobalamin in Table 1 indicates the amount of cyanocobalamin (%) immediately after production and after storage for 1 month when the amount of added cyanocobalamin is 100.
- Example 2 Manufacture of cyanocobalamin-containing capsules by conventional technology
- a cyanocobalamin-containing capsule preparation was produced in the same manner as in Example 4 except that the same amount of Poem S-100 (manufactured by Riken Vitamin Co.) was used instead of Aerosil RX200 in the capsule content of cyanocobalamin of Example 4.
- Example 2 Evaluation after storage Similar to Example 4, the cyanocobalamin content was measured immediately after soft capsule production and after storage for 1 month. The results are shown in Table 2. The amount of cyanocobalamin in Table 2 indicates the amount of cyanocobalamin (%) immediately after production and after storage for 1 month when the amount of added cyanocobalamin is 100.
- the hydrophilic substance can be stably retained for a long period of time and the film softened by dissolving the hydrophilic substance in the aqueous solution. It became clear that it was possible to prevent. Furthermore, if the capsule preparation of the present invention is used, the hydrophilic substance can be dissolved in the aqueous solution, so that the hydrophilic substance can be prevented from deteriorating even when the hydrophilic substance and the incompatible ingredients are mixed into the capsule contents. Became clear.
- the capsule preparation of the present invention can be used as a capsule preparation that can stably retain a hydrophilic substance for a long period of time in the fields of medicine, quasi-drug, food, and the like.
Abstract
Description
本発明のカプセル製剤によりカプセル中に水溶液を安定に保持できるか否かを確認するために、寒天微粒を用いてカプセル製剤を製造し、カプセル製剤を保存後の寒天の状態を調べた。
水100重量部に対して寒天1重量部、赤色102号0.01重量部を添加し、95℃で加温溶解して寒天微粒用寒天溶液を得た。
シームレス式ソフトカプセル製造装置を用いて前記寒天微粒用寒天溶液を滴下し、直径約1mmの柔らかい寒天微粒を製造した。
水90重量部に、グリセリン30重量部及びゼラチン100重量部を加えて吸水膨潤させた後、80℃で加温溶解してカプセル皮膜液を得た。
MCT(ココナードMT、花王社製)100重量部に対し、アエロジルRX200(日本アエロジル社製)10重量部を添加し、攪拌機を用いて撹拌した。その後、上記寒天微粒を5重量部加え、さらに混合することでカプセル内容物を得た。
ロータリーダイ式ソフトカプセル製造装置により、前記カプセル内容物を前記カプセル皮膜液で被包し、その後30℃で20時間乾燥させることにより寒天微粒含有ソフトカプセルを製造した。得られた寒天微粒含有ソフトカプセル1球には、10粒前後の寒天微粒が内包されていた。寒天微粒は、カプセル製造における乾燥工程後でも柔らかく、水分を保持していた。
得られた寒天微粒含有ソフトカプセルを40℃で6カ月間保存した。保存後の寒天微粒含有ソフトカプセルの写真を図1に示す。カプセル内容物中の矢印で示す点が寒天微粒である。保存後の寒天微粒含有ソフトカプセルに内包された寒天微粒を観察すると、カプセル製造直後の寒天微粒含有ソフトカプセルに内包された寒天微粒と同程度に柔らかく、同程度に水分を保持していた。さらに、皮膜の軟化は生じなかった。
(従来技術による寒天微粒含有カプセルの製造)
実施例1のカプセル内容物において、アエロジルRX200に代えてミツロウを同量使用する以外は、上記と同様の条件で寒天微粒含有ソフトカプセルを製造した。得られた寒天微粒含有ソフトカプセル1球には、10粒前後の寒天微粒が内包されていた。寒天微粒は、製造直後は柔らかく、水分を保持していた。
得られた寒天微粒含有ソフトカプセルを40℃で6カ月間保存した。保存後のソフトカプセルは皮膜が軟化し、カプセル同士が融着していた。また寒天微粒は水分が蒸発し、残渣のみが観察された。
MCT(ココナードMT、花王社製)83重量部にアエロジル380(日本アエロジル社製)7重量部を加え、ホモミキサーを用いて2000rpmで5分間撹拌した。得られた混合液に、着色した水10重量部を加え、再び2000rpmで5分間撹拌して分散液を得た。
MCT(ココナードMT、花王社製)85重量部にアエロジル200(日本アエロジル社製)5重量部を加え、ホモミキサーを用いて2000rpmで5分間撹拌した。得られた混合液に、着色した水10重量部を加え、再び2000rpmで5分間撹拌して分散液を得た。
親水性ビタミンであるシアノコバラミンを水に溶解させた水溶液と、コバラミン類を劣化させるチアミン類及びピリドキシン類とを同一カプセル内に含有するカプセル製剤を製造し、シアノコバラミンの劣化を調べた。なお、シアノコバラミンの劣化とは、分解などによりシアノコバラミンの量が低下することを意味する。
MCT(ココナードMT、花王製)1654.68重量部を60℃に加温し、アエロジルRX200(日本アエロジル社製)116.1重量部を添加して水冷しながら攪拌機を用いて撹拌した。シアノコバラミン1%水溶液6重量部、フルスルチアミン塩酸塩109.16重量部、ピリドキシン塩酸塩20重量部、コンドロイチン硫酸エステルナトリウム800重量部を添加し、さらに混合撹拌した。その後、コロイドミルにて粉砕し、真空脱泡して、アエロジルを含有するMCTにシアノコバラミン水溶液が内包されたカプセル内容物を得た。
ロータリーダイ式ソフトカプセル製造装置により、実施例1に記載したカプセル皮膜液及び上記シアノコバラミン水溶液が内包されたカプセル内容物を用いてソフトカプセルを製造した。
得られたシアノコバラミン含有ソフトカプセル製剤を40℃で1カ月間保存した。保存後のソフトカプセルにおいて、水溶液はカプセル製造直後と同量を維持し、皮膜の軟化は生じなかった。また、ソフトカプセル製造直後及び1ヶ月保存後のシアノコバラミン量を、高速液体クロマトグラフィー法を用いて測定した。結果を表1に示す。表1におけるシアノコバラミン量は、添加したシアノコバラミン量を100とした場合の、製造直後及び1ヶ月保存後のシアノコバラミン量(%)を示す。
(従来技術によるシアノコバラミン含有カプセルの製造)
実施例4のシアノコバラミン含有カプセル内容物において、アエロジルRX200に代えてポエムS-100(理研ビタミン社製)を同量使用する以外は、実施例4と同様の方法でシアノコバラミン含有カプセル製剤を製造した。
実施例4と同様に、ソフトカプセル製造直後及び1ヶ月保存後のシアノコバラミン含有量を測定した。結果を表2に示す。表2におけるシアノコバラミン量は、添加したシアノコバラミン量を100とした場合の、製造直後及び1ヶ月保存後のシアノコバラミン量(%)を示す。
Claims (4)
- 多孔性微粒子粉末を含有する油性物質に水溶液が内包されたカプセル用内容物を親水性皮膜で被包したカプセル製剤。
- 油性物質100重量部に対して多孔性微粒子粉末0.1~20重量部を含有している、請求項1記載のカプセル製剤。
- カプセル製剤がソフトカプセル製剤である、請求項1又は2記載のカプセル製剤。
- 多孔性微粒子粉末が気相法シリカである、請求項1~3のいずれか記載のカプセル製剤。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/113,865 US20160331695A1 (en) | 2014-01-31 | 2015-01-22 | Capsule Formulation |
JP2015559812A JP6483031B2 (ja) | 2014-01-31 | 2015-01-22 | カプセル製剤 |
EP15742744.4A EP3100721B1 (en) | 2014-01-31 | 2015-01-22 | Capsule formulation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-017685 | 2014-01-31 | ||
JP2014017685 | 2014-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015115072A1 true WO2015115072A1 (ja) | 2015-08-06 |
Family
ID=53756657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/000291 WO2015115072A1 (ja) | 2014-01-31 | 2015-01-22 | カプセル製剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20160331695A1 (ja) |
EP (1) | EP3100721B1 (ja) |
JP (1) | JP6483031B2 (ja) |
WO (1) | WO2015115072A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018043661A1 (ja) * | 2016-09-05 | 2018-03-08 | 富士カプセル株式会社 | 寒天皮膜カプセル |
WO2018135551A1 (ja) | 2017-01-17 | 2018-07-26 | 森下仁丹株式会社 | 水含有カプセル、並びに水含有カプセルの製造方法 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5480407A (en) * | 1977-11-03 | 1979-06-27 | Hoechst Ag | Method and apparatus for producing medical preparation |
JPS59139317A (ja) | 1983-01-31 | 1984-08-10 | Teisan Seiyaku Kk | 持続性のニフエジピン製剤 |
JPS61151127A (ja) | 1984-12-25 | 1986-07-09 | Meiji Milk Prod Co Ltd | ビフイズス菌含有ソフトカプセルの製造方法 |
JPH0352639A (ja) | 1989-07-20 | 1991-03-06 | Morishita Jintan Kk | 親水性物質を内容物とするシームレスカプセルおよびその製法 |
JPH0368508A (ja) | 1989-04-07 | 1991-03-25 | L'oreal Sa | アルギナートカプセルの製造方法、その製造装置及び該カプセルを含有する化粧用組成物 |
JPH06247845A (ja) | 1993-02-25 | 1994-09-06 | Fuji Capsule Kk | 微粒子性酸化ケイ素配合軟カプセル剤 |
JPH0834727A (ja) | 1994-07-25 | 1996-02-06 | Kureha Chem Ind Co Ltd | 被覆軟カプセル |
JPH08511559A (ja) * | 1993-06-18 | 1996-12-03 | スミスクライン・ビーチャム・コーポレイション | 軟外皮ゼラチンに封入された粒子 |
JPH0925228A (ja) | 1995-07-13 | 1997-01-28 | Eisai Co Ltd | シームレスソフトカプセル |
JP2002519370A (ja) * | 1998-07-07 | 2002-07-02 | ピエール、ファーブル、メディカマン | 硬カプセル充填用チキソトロピー製剤 |
JP2005501914A (ja) * | 2001-09-10 | 2005-01-20 | エフ.ホフマン−ラ ロシュ アーゲー | 油性チキソトロープ性配合物 |
CN102133406A (zh) * | 2011-03-17 | 2011-07-27 | 江苏京甲药业有限公司 | 阿片类药物油相制剂及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0212875A3 (en) * | 1985-08-12 | 1988-06-15 | William Gough Tucker | Medicinal composition and method of making same |
US6228894B1 (en) * | 1998-04-17 | 2001-05-08 | Enhanced Derm Technologies, Inc. | Softgel-compatible composition containing retinol |
US5891470A (en) * | 1998-04-17 | 1999-04-06 | Advanced Polymer Systems, Inc. | Softgel formulation containing retinol |
US20080268039A1 (en) * | 2007-03-06 | 2008-10-30 | Soft Gel Technologies, Inc. | Loquat compositions |
WO2008126477A1 (ja) * | 2007-03-30 | 2008-10-23 | Powdertech Co., Ltd. | 無機粒子含有エマルション及び無機粒子含有エマルションを用いた粒子の製造方法 |
-
2015
- 2015-01-22 US US15/113,865 patent/US20160331695A1/en not_active Abandoned
- 2015-01-22 JP JP2015559812A patent/JP6483031B2/ja active Active
- 2015-01-22 WO PCT/JP2015/000291 patent/WO2015115072A1/ja active Application Filing
- 2015-01-22 EP EP15742744.4A patent/EP3100721B1/en active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5480407A (en) * | 1977-11-03 | 1979-06-27 | Hoechst Ag | Method and apparatus for producing medical preparation |
JPS59139317A (ja) | 1983-01-31 | 1984-08-10 | Teisan Seiyaku Kk | 持続性のニフエジピン製剤 |
JPS61151127A (ja) | 1984-12-25 | 1986-07-09 | Meiji Milk Prod Co Ltd | ビフイズス菌含有ソフトカプセルの製造方法 |
JPH0368508A (ja) | 1989-04-07 | 1991-03-25 | L'oreal Sa | アルギナートカプセルの製造方法、その製造装置及び該カプセルを含有する化粧用組成物 |
JPH0352639A (ja) | 1989-07-20 | 1991-03-06 | Morishita Jintan Kk | 親水性物質を内容物とするシームレスカプセルおよびその製法 |
JPH06247845A (ja) | 1993-02-25 | 1994-09-06 | Fuji Capsule Kk | 微粒子性酸化ケイ素配合軟カプセル剤 |
JPH08511559A (ja) * | 1993-06-18 | 1996-12-03 | スミスクライン・ビーチャム・コーポレイション | 軟外皮ゼラチンに封入された粒子 |
JPH0834727A (ja) | 1994-07-25 | 1996-02-06 | Kureha Chem Ind Co Ltd | 被覆軟カプセル |
JPH0925228A (ja) | 1995-07-13 | 1997-01-28 | Eisai Co Ltd | シームレスソフトカプセル |
JP2002519370A (ja) * | 1998-07-07 | 2002-07-02 | ピエール、ファーブル、メディカマン | 硬カプセル充填用チキソトロピー製剤 |
JP2005501914A (ja) * | 2001-09-10 | 2005-01-20 | エフ.ホフマン−ラ ロシュ アーゲー | 油性チキソトロープ性配合物 |
CN102133406A (zh) * | 2011-03-17 | 2011-07-27 | 江苏京甲药业有限公司 | 阿片类药物油相制剂及其制备方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3100721A4 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018043661A1 (ja) * | 2016-09-05 | 2018-03-08 | 富士カプセル株式会社 | 寒天皮膜カプセル |
JPWO2018043661A1 (ja) * | 2016-09-05 | 2019-06-24 | 富士カプセル株式会社 | 寒天皮膜カプセル |
WO2018135551A1 (ja) | 2017-01-17 | 2018-07-26 | 森下仁丹株式会社 | 水含有カプセル、並びに水含有カプセルの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US20160331695A1 (en) | 2016-11-17 |
JP6483031B2 (ja) | 2019-03-13 |
EP3100721A1 (en) | 2016-12-07 |
EP3100721A4 (en) | 2017-09-06 |
JPWO2015115072A1 (ja) | 2017-03-23 |
EP3100721B1 (en) | 2020-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021088460A1 (zh) | 一种载益生菌的微胶囊的制备方法及由其制得产品和应用 | |
CN105828806A (zh) | 制剂 | |
JP2021523917A (ja) | 不透明化剤を含むカプセル | |
Chan et al. | Microencapsulation of oils using sodium alginate | |
EP0768870A1 (en) | Multiple encapsulation of oleophilic substances | |
JP6468633B2 (ja) | 三層構造シームレスカプセル | |
JP4982178B2 (ja) | マイクロカプセル封入系およびその適用 | |
JP2012520173A (ja) | コロイド状粒子のような粒子を使用するテンプレーティングのシステムおよび方法 | |
JP6483031B2 (ja) | カプセル製剤 | |
JP6681918B2 (ja) | カプセルの製造方法 | |
CN103251572A (zh) | 茶黄素肠溶微囊的制备方法及其制得的产品和应用 | |
Goyal et al. | Preparation and evaluation of calcium silicate based floating microspheres of amoxicillin | |
CA2516448A1 (en) | Method for preparation of an agglomerate using melt agglomeration | |
JP6258716B2 (ja) | 疎水性ゲルを含有するソフトカプセル製剤 | |
JP6056114B2 (ja) | 油状物質含有粉末組成物 | |
Sultana et al. | Encapsulation of Tocotrienol-Enriched Flaxseed Oil in Calcium Alginate–Carboxymethyl Cellulose Hydrogel Beads for Improved Oxidative Stability and Release Profile | |
JP7222548B2 (ja) | 三層構造シームレスカプセル | |
Nehe et al. | Review on: Novel solid self nanoemulsifying drug delivery system | |
JP4189921B2 (ja) | 油性粒子の製造方法 | |
Palamarchuk et al. | Microcapsules Based on Pickering Emulsion and Polyelectrolyte Layers: Biomedical Applications | |
JP7219617B2 (ja) | 難溶性薬物の微粒子を含有する医薬組成物の製造方法 | |
Ibrahim et al. | Self-emulsifying drug delivery formulations | |
CN106924228B (zh) | 一种姜黄素组合物及其制备方法和应用 | |
JP6640966B2 (ja) | 三層構造シームレスカプセル | |
WO2008131506A1 (en) | Mucoadhesive granules containing chitosan nano- and/or microspheres and the process of manufacture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15742744 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015559812 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015742744 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015742744 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15113865 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |